AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6859669
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume (V(T)) of 14 ml/kg
Trial: 6859669
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume (V(T)) of 11 ml/kg
Trial: 6859669
Drug: Tidal volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volume (V(T)) of 7 ml/kg
Trial: 6859669
Drug: High tidal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High tidal volume (>12 ml/kg)
Trial: 28264692
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) provided by a multidisciplinary team
Trial: 28264692
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) provided by a multidisciplinary team and Short Message Service (SMS)
Trial: 25919473
Drug: Combined intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intra-articular and rotator interval injection
Trial: 25919473
Drug: Intra-articular corticosteroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular corticosteroid injection and Combined intra-articular/interval injection
Trial: 21279511
Drug: Glutamine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (3 g/day)
Trial: 23062837
Drug: Atomoxetine (ATX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX), mean daily dosage 71.6±14.9mg, treatment duration 12 weeks
Trial: 21741092
Drug: Grass AIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass AIT (Phleum pratense grass pollen allergen extract), once-daily for 8 to 10 weeks
Trial: 1328364
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg) + Benazepril (10 mg)
Trial: 6108817
Drug: SKF 92
RxNorm normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKF 92 657 at 1.0 mg/kg
Trial: 6108817
Drug: SKF 92
RxNorm normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKF 92 657 at 2.0 mg/kg
Trial: 6108817
Drug: SKF 92
RxNorm normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKF 92 657 at 4.0 mg/kg
Trial: 6108817
Drug: SKF 92
RxNorm normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKF 92 657 at 8.0 mg/kg
Trial: 31159849
Drug: ASICA intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASICA intervention (tablet-based digital intervention to prompt and support TSSE)
Trial: 27853163
Drug: Sacubitril/valsartan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan 200 mg QD, uptitrated to 400 mg QD if BP uncontrolled after 4 weeks, followed by amlodipine 5-10 mg and hydrochlorothiazide 6.25-25 mg if needed
Trial: 27853163
Drug: Sacubitril/valsartan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan 200 mg QD
Trial: 25483230
Drug: Lutein and
RxNorm normalized name: ICaps Lutein and Omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein and Zeaxanthin supplements (n=54)
Trial: 19845256
Drug: Topical 10%
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10% phenylephrine cream
Trial: 19845256
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (Control)
Trial: 10524837
Drug: Lamotrigine 50
RxNorm normalized name: lamotrigine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 50 mg/day
Trial: 6786071
Drug: Protein-calorie replacement
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-calorie replacement therapy (immediate sensitization to dinitrochlorobenzene)
Trial: 6786071
Drug: Protein-calorie replacement
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-calorie replacement therapy (sensitization after 1 week)
Trial: 6786071
Drug: Protein-calorie replacement
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-calorie replacement therapy (sensitization after 2 weeks)
Trial: 6786071
Drug: Protein-calorie replacement
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-calorie replacement therapy (sensitization after 3 weeks)
Trial: 6786071
Drug: Attempted sensitization
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attempted sensitization before refeeding in children with total serum proteins < 4.5 g/dl
Trial: 28549665
Drug: High nitrate‐containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High nitrate‐containing beetroot juice (BRJ) consumed daily (8 mmol nitrate for HTN) or three times a week (6.1 mmol nitrate for HFpEF)
Trial: 25163639
Drug: Probiotic preparation
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic preparation containing Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium lactis, fructooligosaccharide, galactooligosaccharide, colostrums and lactoferrin (NBL probiotic ATP®)
Trial: 23474363
Drug: Capecitabine (830
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (830 mg/m² twice daily, Monday to Friday) with radiation (50.4 Gy in 28 fractions)
Trial: 23474363
Drug: Gemcitabine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (300 mg/m² once per week) with radiation (50.4 Gy in 28 fractions)
Trial: 21320365
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g RBO spread (RBOS)
Trial: 21320365
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g phytosterol-enriched spread (PS)
Trial: 21320365
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g standard spread (SS)
Trial: 21320365
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g RBOS plus 30 ml RBO
Trial: 21320365
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g SS plus 30 ml sunflower oil
Trial: 16928840
Drug: No spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No spray (control)
Trial: 10788675
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light treatment (2-h exposure to 2500 lux between 14.00 and 16.00 h)
Trial: 10788675
Drug: Physical exercise
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical exercise and bright light treatment
Trial: 8840941
Drug: Intravenous push
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous push of iron dextran 100 mg over 2 minutes (undiluted)
Trial: 8840941
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of iron dextran 100 mg over 30 minutes
Trial: 8840941
Drug: Cost-minimization analysis
RxNorm normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-minimization analysis of intravenous push administration
Trial: 6401911
Drug: Cysteine‐HCl supplemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteine‐HCl supplemented total parenteral nutrition
Trial: 30382737
Drug: iDOVE intervention
RxNorm normalized name: Dove DermaSeries
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iDOVE intervention (cognitive-behavioral therapy and motivational interviewing-based intervention with a brief in-ED session and 8 weeks of automated text-message daily mood queries)
Trial: 30382737
Drug: Control (brief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (brief in-ED presentation and twice-weekly text messages on healthy behaviors)
Trial: 27022679
Drug: Oral 50,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 50,000 IU/wk Vitamin D3 (cholecalciferol) for 52 weeks
Trial: 27022679
Drug: Oral 50,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 50,000 IU/wk Vitamin D3 (cholecalciferol) for 52 weeks (stratified by depression types)
Trial: 20630682
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (nadroparin 180 anti-activated factor X units once daily for 10 days) plus compression therapy for three months
Trial: 9203881
Drug: Neostigmine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (100 micrograms in 1 ml of saline)
Trial: 9203881
Drug: Morphine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (100 micrograms in 1 ml of saline)
Trial: 7970115
Drug: Individualized dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized dialysis prescription using urea kinetic modelling (UKM)
Trial: 3308737
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (1 g twice daily)
Trial: 3308737
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Calcium and Ascorbic acid)
Trial: 25200399
Drug: AREDS formulation
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AREDS formulation (AF)
Trial: 20048183
Drug: Idarubicin (IDA3;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDA3; 12 mg/m(2)/d x 3 days)
Trial: 20048183
Drug: Idarubicin (IDA4;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDA4; 12 mg/m(2)/d x 4 days)
Trial: 20048183
Drug: Daunorubicin (DNR;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin (DNR; 80 mg/m(2)/d x 3 days)
Trial: 20048183
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of idarubicin (IDA3; 12 mg/m(2)/d x 3 days)
Trial: 20048183
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with rIL-2
Trial: 16635225
Drug: rhIL-11 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-11 (1 mg once weekly)
Trial: 16635225
Drug: prednisolone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisolone (60 mg/day)
Trial: 12792544
Drug: GoreTex (W.L.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GoreTex (W.L. Gore) repair
Trial: 2024739
Drug: Secobarbital (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secobarbital (100 mg daily)
Trial: 2024739
Drug: Secobarbital (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secobarbital (200 mg daily)
Trial: 2024739
Drug: Ethanol (1
RxNorm normalized name: ALCOHOL 95 mL in 100 mL TOPICAL SOLUTION [95% Ethanol (190 Proof)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (1 g/kg daily)
Trial: 6120716
Drug: Intravenous propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propranolol or metoprolol
Trial: 6120716
Drug: Intravenous frusemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous frusemide
Trial: 6120716
Drug: Prior oral
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior oral metoprolol or propranolol
Trial: 24702815
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (0.4 U/kg therapeutic dose)
Trial: 24702815
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (0.8 U/kg high dose)
Trial: 18626423
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 4 mg (0.1 cc) of triamcinolone acetonide at the end of surgery
Trial: 12403927
Drug: Established antihistamine
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Established antihistamine treatment
Trial: 9972747
Drug: Routine transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine transfusion therapy
Trial: 8788983
Drug: Baclofen (GABA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (GABA receptor ligand) for 3 weeks
Trial: 8788983
Drug: Sybazon preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sybazon preparation
Trial: 2260157
Drug: Nimodipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (2 mg/hr constant intravenous infusion for 5 days, 120 mg/day orally for another 16 days)
Trial: 6355877
Drug: Extensive plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extensive plasma exchanges (PE) plus conventional corticosteroid/azathioprine treatment
Trial: 6355877
Drug: Conventional corticosteroid/azathioprine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional corticosteroid/azathioprine treatment
Trial: 27743448
Drug: Long-term weekly
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term weekly supragingival irrigations with aerosolized 0.5% hydrogen peroxide
Trial: 25373733
Drug: Bortezomib plus
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib plus Bevacizumab (15 mg/kg Bevacizumab and 1.3 mg/m2 Bortezomib)
Trial: 7484032
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 1% mepivacaine (10 mg/ml)
Trial: 7484032
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml of 1% mepivacaine (10 mg/ml)
Trial: 7372262
Drug: Solugastril Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solugastril Gel (3 sachets daily)
Trial: 7372262
Drug: Solugastril Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solugastril Gel combined with Solu-Vetan
Trial: 28800989
Drug: Intraluminal placement
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraluminal placement of 9-French Arndt bronchial blocker
Trial: 28800989
Drug: Extraluminal placement
RxNorm normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraluminal placement of 9-French Arndt bronchial blocker
Trial: 26308766
Drug: Positive antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive antibody titers postinduction
Trial: 26308766
Drug: Negative antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative antibody titers
Trial: 26308766
Drug: Positive antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive antibody titers
Trial: 16622270
Drug: Neoadjuvant (primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant (primary systemic) treatment for operable breast cancer
Trial: 8256886
Drug: Thiorphan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiorphan (2.5 mg/ml concentration, 0.5 ml nebulized dose)
Trial: 29514306
Drug: Monovalent rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent rotavirus vaccine
Trial: 26329347
Drug: Telmisartan/rosuvastatin fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan/rosuvastatin fixed-dose combination (80/20 mg)
Trial: 26329347
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of telmisartan 80 mg and rosuvastatin 20 mg
Trial: 18498589
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of dental implants
Trial: 20467623
Drug: Early loading
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early loading of dental implants (6 weeks)
Trial: 12580841
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% 20 mL injected into the uterus, fallopian tubes, and pelvis
Trial: 12580841
Drug: Placebo normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo normal saline 20 mL injected into the uterus, fallopian tubes, and pelvis
Trial: 11113041
Drug: abciximab with
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: abciximab with standard-dose weight-adjusted heparin
Trial: 11113041
Drug: placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo with standard-dose weight-adjusted heparin
Trial: 1418046
Drug: 1% flutrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% flutrimazole skin cream
Trial: 1418046
Drug: 2% flutrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% flutrimazole skin cream
Trial: 1418046
Drug: 1% clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clotrimazole commercial skin cream
Trial: 3856293
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg PGE2
Trial: 3856293
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg PGE2
Trial: 27348915
Drug: Needle-pricking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-pricking therapy at Guanyuan (CV 4) and bilateral sacral plexus nerve, lumbar 1 nerve and greater occipital nerve stimulating points, once a week for 9 weeks
Trial: 27348915
Drug: Midodrine tablets
RxNorm normalized name: midodrine Oral Tablet
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midodrine tablets prescribed orally, three times a day for 9 weeks
Trial: 24721240
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine Liuweiwuling tablets in combination with entecavir
Trial: 1283552
Drug: Nurse-administered intermittent
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered intermittent intramuscular (IM) injections of morphine
Trial: 3004550
Drug: Antituberculous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antituberculous chemotherapy (2-week course)
Trial: 3004550
Drug: Antituberculous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antituberculous chemotherapy including rifampicin
Trial: 3004550
Drug: Antituberculous chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antituberculous chemotherapy without rifampicin
Trial: 31295009
Drug: Xinmailong injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinmailong injection (100 mg/2 mL, intravenous drip infusion)
Trial: 31295009
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus XI
Trial: 22702508
Drug: SCH527123, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH527123, 30 mg daily PO
Trial: 15735456
Drug: Oral fluid
RxNorm normalized name: cascara sagrada ORAL FLUID EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluid test with standard counseling
Trial: 3294284
Drug: Intravenous dextro‐amphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dextro‐amphetamine
Trial: 29569470
Drug: In-hospital consultation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital consultation using the home and community environment assessment and the Lawton Instrumental Activities of Daily Living assessment
Trial: 20356395
Drug: Conventional therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapeutic exercise classes (12 weekly sessions)
Trial: 18344733
Drug: Olanzapine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (mean dose 11.3 mg)
Trial: 18344733
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean dose 3.0 mg)
Trial: 16546280
Drug: IH636 grape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IH636 grape seed proanthocyanidin extract (GSPE) 100 mg three times a day orally for 6 months
Trial: 10714421
Drug: Exercise group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise group (rehabilitation program consisting of exercise and education twice a week for 8 weeks)
Trial: 8330466
Drug: CGS-12970 (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGS-12970 (100, 200, 300, or 400 mg twice a day)
Trial: 27418249
Drug: Intermittent occlusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent occlusion therapy (IO therapy) using liquid crystal glasses (Amblyz), 4 hours per day, set at 30‐second opaque/transparent intervals (occluded 50% of wear time)